Lupivor 20mg Tablet contains vortioxetine, a multimodal antidepressant indicated for the treatment of major depressive disorder (MDD) in adults. Vortioxetine acts by modulating the activity of serotonin receptors and inhibiting the serotonin transporter, thereby enhancing serotonergic neurotransmission in the central nervous system. This pharmacological profile contributes to its antidepressant and anxiolytic effects, improving mood, cognitive function, and overall quality of life in patients with depression. Lupivor is administered orally, typically once daily, with or without food. The recommended dose is 20 mg per day, adjusted according to clinical response and tolerability. Common adverse effects include nausea, headache, dizziness, and diarrhea, which are generally mild to moderate and transient. Caution is advised when prescribing Lupivor concomitantly with other serotonergic agents due to the risk of serotonin syndrome. It is contraindicated in patients with hypersensitivity to vortioxetine or any excipients. Use during pregnancy and lactation should be considered only if the potential benefit justifies the potential risk to the fetus or infant. Regular monitoring of clinical response and side effects is recommended to optimize treatment outcomes. Lupivor 20mg Tablet offers an effective therapeutic option for managing depression with a favorable safety profile.